LENG8-AS1: A Potential Drug Target and Biomarker (G104355426)

Target Name: LENG8-AS1

NCBI ID: G104355426

LENG8-AS1

Other Name(s): LENG8 antisense RNA 1

LENG8-AS1: A Potential Drug Target and Biomarker

Introduction

LENG8-AS1, also known as LENG8-1, is a non-coding RNA molecule that has been identified as an antisense RNA 1 in the LENG8 gene, which is located on chromosome 8. This RNA molecule has been shown to play a critical role in the regulation of gene expression and has been associated with various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

The discovery of LENG8-AS1

The LENG8 gene is located on chromosome 8 and encodes for the protein LENG8, which is a member of the TATA-binding protein (TBP) family. LENG8 is known to play a critical role in the regulation of gene expression and has been associated with the development and progression of various diseases.

In recent years, researchers have identified LENG8-AS1 as a non-coding RNA molecule that is expressed in various tissues and cells, including the brain, liver, and pancreas. The RNA molecule has been shown to interact with the protein encoded by the LENG8 gene and has been shown to play a critical role in the regulation of gene expression.

The potential implications of LENG8-AS1 as a drug target

The discovery of LENG8-AS1 has significant implications for the development of new drugs and biomarkers for various diseases. LENG8-AS1 has been shown to play a critical role in the regulation of gene expression and has been associated with the development and progression of various diseases. . Therefore, targeting LENG8-AS1 may be a promising strategy for the development of new drugs that can treat these diseases.

One potential mechanism by which LENG8-AS1 could be targeted with drugs is by inhibiting its activity as an RNA binding protein. LENG8-AS1 has been shown to interact with various proteins, including the protein encoded by the LENG8 gene. Therefore, drugs that can inhibit the activity of LENG8-AS1 and prevent it from binding to other proteins may be effective in treating diseases associated with LENG8-AS1-mediated gene expression.

Another potential mechanism by which LENG8-AS1 could be targeted with drugs is by modulating its expression levels. LENG8-AS1 has been shown to be expressed in various tissues and cells, including the brain, liver, and pancreas. Therefore, drugs that can modulate the expression levels of LENG8-AS1 in specific tissues or cells may be effective in treating diseases associated with LENG8-AS1-mediated gene expression.

The potential implications of LENG8-AS1 as a biomarker

The discovery of LENG8-AS1 has also significant implications for the development of new biomarkers for various diseases. LENG8-AS1 has been shown to play a critical role in the regulation of gene expression and has been associated with the development and progression of various diseases. Therefore, measuring the levels of LENG8-AS1 in tissues or cells may be a useful biomarker for the diagnosis and prognosis of these diseases.

One potential application of LENG8-AS1 as a biomarker is in the diagnosis of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These diseases are characterized by the progressive loss of brain cells and can be treated with drugs that target the underlying molecular mechanisms that cause the disease. Measurement of the levels of LENG8-AS1 in brain tissues or fluids may be a useful biomarker for the diagnosis and prognosis of these diseases.

Another application of LENG8-AS1 as a biomarker is in the diagnosis of autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis. These potential disorders are characterized by the immune system attacking the body's own tissues, leading to inflammation and joint damage. Measurement of the levels

Protein Name: LENG8 Antisense RNA 1

The "LENG8-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LENG8-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets